Fernanda Santos Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernanda Santos Fernandes has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ana Luiza Mansur
Eleve Science Pesquisa e Desenvolvimento Supera Innovation and Technology Park, Supera Parque Av. Dra. Nadir Aguiar, n. 1805, Ribeirão Preto, São Paulo 14056-680, Brazil
1 shared publication- Anderson Rodrigo Moraes de Oliveira
Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901, Ribeirao Preto, SP, Brazil
1 shared publication - Arthur Barcelos Ribeiro
University of Franca, Franca, Brazil
1 shared publication Denise Crispim Tavares
University of Franca, Av. Dr. Armando Salles Oliveira, N. 201, Franca, São Paulo 14404-600, Brazil
1 shared publication- Denise Crispim Tavares
Universidade de Franca
1 shared publication - Eduardo Jose Nassar
Hybrid Lamellar Materials Research Group (GPMatLam), Parque Universitário, University of Franca, Av. Dr. Armando Salles Oliveira, 201, Franca 14404-600, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 21 March 2022
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 173, 106173
Pharmacokinetic study of AmB-NP-GR: A new granule form with amphotericin B to treat leishmaniasis and fungal infections
- 21 March 2022
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 173, 106173
Open AccessPharmacokinetic study of AmB-NP-GR: A new granule form with amphotericin B to treat leishmaniasis and fungal infections
- 23 August 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (9) , 1-11
Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles
Melanoma is the deadliest type of skin cancer. Treatments that directly address tumor survival are required. Indomethacin (IND) is a well-known drug used worldwide. Although widely used as a therapeutic agent, IND has undesirable gastrointestinal effects. Purpose To investigate the antitumor efficacy of IND incorporated into mesoporous silica nanoparticles (MSNPs+IND), as well as its toxic potential in a syngeneic murine B16 melanoma model. Methods Antitumor activity was evaluated by measuring tumor size and weight and by histopathological analysis. Possible molecular signaling pathways involved in the antitumor activity were analyzed by Western blot in liver tissue and by immunohistochemistry in tumor tissue. The potential toxicity was evaluated by determining body and organ weights and by biochemical and genotoxic analysis. Results MSNPs+IND treatments inhibited tumor growth by up to 70.09% and decreased the frequency of mitosis in tumor tissues, which was up to 37.95% lower compared to the IND groups. In hepatic tissue, COX-2 levels decreased significantly after treatment with MSNPs+IND and IND. Additionally, MSNPs+IND and IND increased the levels of cleaved caspase-3 (156.25% and 137.50%, respectively), inducing tumor cell apoptosis. Genotoxicity was limited to the group treated with the higher concentration of IND, while MSNPs prevented IND-induced genotoxicity. Conclusions MSNPs may be promising for future applications in cancer therapy.
- 23 August 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (9) , 1-11
Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles
Melanoma is the deadliest type of skin cancer. Treatments that directly address tumor survival are required. Indomethacin (IND) is a well-known drug used worldwide. Although widely used as a therapeutic agent, IND has undesirable gastrointestinal effects. Purpose To investigate the antitumor efficacy of IND incorporated into mesoporous silica nanoparticles (MSNPs+IND), as well as its toxic potential in a syngeneic murine B16 melanoma model. Methods Antitumor activity was evaluated by measuring tumor size and weight and by histopathological analysis. Possible molecular signaling pathways involved in the antitumor activity were analyzed by Western blot in liver tissue and by immunohistochemistry in tumor tissue. The potential toxicity was evaluated by determining body and organ weights and by biochemical and genotoxic analysis. Results MSNPs+IND treatments inhibited tumor growth by up to 70.09% and decreased the frequency of mitosis in tumor tissues, which was up to 37.95% lower compared to the IND groups. In hepatic tissue, COX-2 levels decreased significantly after treatment with MSNPs+IND and IND. Additionally, MSNPs+IND and IND increased the levels of cleaved caspase-3 (156.25% and 137.50%, respectively), inducing tumor cell apoptosis. Genotoxicity was limited to the group treated with the higher concentration of IND, while MSNPs prevented IND-induced genotoxicity. Conclusions MSNPs may be promising for future applications in cancer therapy.